Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma ; volume:14 ; number:2 ; year:2021 ; pages:1051-1058 ; extent:8
Case reports in oncology ; 14, Heft 2 (2021), 1051-1058 (gesamt 8)
- Creator
-
Shields, Lisa B.E.
Alsorogi, Mohammad S.
Mar, Nataliya
Rezazadeh Kalebasty, Arash
- DOI
-
10.1159/000513001
- URN
-
urn:nbn:de:101:1-2021090900432729608396
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shields, Lisa B.E.
- Alsorogi, Mohammad S.
- Mar, Nataliya
- Rezazadeh Kalebasty, Arash
Other Objects (12)
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Visceral Leishmaniasis in a 62-Year-Old Woman with Metastatic Renal Cancer in Treatment with Nivolumab
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Visceral Leishmaniasis in a 62-Year-Old Woman with Metastatic Renal Cancer in Treatment with Nivolumab
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Visceral Leishmaniasis in a 62-Year-Old Woman with Metastatic Renal Cancer in Treatment with Nivolumab